ArticleJournal of robotic surgery2026
Transoral robotic thyroidectomy vs. Open thyroidectomy for thyroid cancer: A propensity Score-Matched analysis.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Transoral robotic thyroidectomy (TORT) offers a virtually scarless outcome but requires comparative validation studies against open thyroidectomy (OT). Patients who underwent thyroid surgery at our institution between January 2020 and October 2024 were enrolled. Through propensity score matching analysis, a final cohort of 322 adults with pathologically confirmed thyroid carcinoma was identified, comprising 161 patients in each group. We analyzed and compared clinical outcomes between the two surgical cohorts, along with patient-reported outcomes including Numerical Rating Scale (NRS) for pain, Voice Handicap Index-10 (VHI-10), and Scar Assessment Questionnaire-Cosmetic (SAQCO) for scar satisfaction assessed at 1 week postoperatively. Among the 322 propensity score-matched patients (age: median [IQR]: 41.0 [34.0, 51.0] years vs. 43.0 [34.0, 52.0] years; 231 females [71.7%], 91 males [28.3%]), the TORT group demonstrated significantly higher operative costs (median [IQR]: ¥63,351.0 [60,644.5, 64,948.8] vs. ¥19,009.6 [17,127.7, 21,774.4]; P < .001, BH-corrected q = 0.002) and longer operative duration (mean [SD]: 242.0 [55.8] min vs. 106.3 [38.4] min; mean difference: 136 min, 95% Cl: 125 - 146; P < .001, BH-corrected q = 0.002) compared to the OT group. However, the TORT group had significantly shorter postoperative hospitalization (mean [SD]: 2.8 [1.4] days vs. 3.4 [1.2] days; mean difference: -0.6 days; 95% Cl: 0.31- 0.88; P < .001, BH-corrected q = 0.002) and a lower incidence of transient hypoparathyroidism (5/161 [3.1%] vs. 29/161 [18.0%]; risk difference: -14.9, 95% Cl:-20.3 to -9.5; RR: 0.19, 95% Cl: 0.08 - 0.45); P < .001, BH-corrected q = 0.002). Patient-reported outcomes favored TORT, with significantly lower: NRS pain scores (median [IQR]: 3.0 [2.0, 4.0] vs. 7.0 [6.0, 8.0]; median difference: -4.0, 95% CI: -5.0 to -4.0; P < .001, BH-corrected q = 0.002). VHI-10 scores (median [IQR]: 38.0 [12.0, 59.0] vs. 77.0 [59.0, 89.0]; median difference: -39.0; 95% CI: -42.0 to -29.0; P < .001, BH-corrected q = 0.002). Conversely, scar satisfaction assessed via the SAQCO was significantly higher in the TORT group (median [IQR]: 20.0 [18.0, 23.0] vs. 14.0 [12.0, 17.0]; median difference: 6.0; 95% CI: 5.0 to 6.0; P < .001). No significant intergroup differences existed in lymph nodes harvested (median [IQR]: 7.0 [4.0, 11.0] vs. 8.0 [5.0, 12.0]; P = .06, BH-corrected q = 0.10) or metastatic lymph nodes dissected (median [IQR]: 0 [0, 2] vs. 1 [0, 3]; P = .06, BH-corrected q = 0.10). TORT achieves non-inferior perioperative outcomes compared to OT, with superior cosmetic results, reduced hospitalization duration. However, incurs significantly higher costs and longer operative times.
Indexed as
Identifiers
41854779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.